Rechallenge with intravenous recombinant human erythropoietin can be successful following the treatment of anti-recombinant erythropoietin associated pure red cell aplasia

2014 ◽  
Vol 81 (05) ◽  
pp. 355-358 ◽  
Author(s):  
Kearkiat Praditpornsilpa ◽  
Khajohn Tiranathanakul ◽  
Saengsuree Jootar ◽  
Kriang Tungsanga ◽  
Somchai Eiam-Ong
2021 ◽  
pp. 1-4
Author(s):  
Sijia Li ◽  
Xueqin Chen ◽  
Penghua Hu ◽  
Suijing Wu ◽  
Jianchao Ma ◽  
...  

Anemia is a common complication of chronic kidney disease (CKD). Recombinant human erythropoietin (rHu-EPO) is used extensively in patients with CKD. However, anti-erythropoietin (anti-EPO) antibody has been reported during rHu-EPO treatment, which causes pure red cell aplasia (PRCA). We presented a case of 75-year-old man, who underwent hemodialysis for 2 years. He developed PRCA during rHu-EPO treatment. The rHu-EPO was immediately discontinued, and the patient was given roxadustat treatment. After 6 months of roxadustat treatment, the anti-EPO antibody was disappeared, and hemoglobin recovered normal range. The results suggest that roxadustat can be used to treat patients with anti-EPO antibody-mediated PRCA without immunosuppressive therapy.


2011 ◽  
Vol 126 (2) ◽  
pp. 114-118 ◽  
Author(s):  
Hiroaki Shimizu ◽  
Takayuki Saitoh ◽  
Fumie Ota ◽  
Takahiro Jimbo ◽  
Yoshito Tsukada ◽  
...  

1991 ◽  
Vol 79 (1) ◽  
pp. 125-125 ◽  
Author(s):  
Carlo Finelli ◽  
Giuseppe Visani ◽  
Barbara Gamberi ◽  
Miriam Fogli ◽  
Annarita Cenacchi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document